KRAS inhibitor-resistance in < em > MET < /em > -amplified < em > KRAS < /em > < sup > G12C < /sup > non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms

CONCLUSIONS: MET amplification leads to the development of resistance to KRAS G12C inhibitors in NSCLC. Dual blockade of MET and KRAS G12C could be a treatment option for MET amplified, KRAS G12C-mutated NSCLC.PMID:34365406 | DOI:10.1158/1078-0432.CCR-21-0856

Source: Clinical Cancer Research - August 8, 2021 Category: Cancer & Oncology Authors: Shinichiro Suzuki Kimio Yonesaka Takeshi Teramura Toshiyuki Takehara Ryoji Kato Hitomi Sakai Koji Haratani Junko Tanizaki Hisato Kawakami Hidetoshi Hayashi Kazuko Sakai Kazuto Nishio Kazuhiko Nakagawa Source Type: research